Clinical trial
A Double-blind, Randomized, Multi-center Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of CJ-30061 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Atorvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia
NCT03639480 is registered in ClinicalTrials.gov with HK inno.N Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Randomized, Multi-center Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of CJ-30061 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Atorvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia
- Lead sponsor
- HK inno.N Corporation
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- October 13, 2017
- Completion date
- October 31, 2018
- Enrollment
- 180 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hyperlipidemia, hypertension